Karen Miller, MD
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1508831488
Payments from drug & device makers
What this record shows
This record is dominated by education: $97 of the $119 with a category attached, or 81.4%. Novo Nordisk accounts for 81.4% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2021 at $65 and has fallen 65.6% since, to $22 in 2024. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MA, where the typical reported total is $583.
Across 4 payments — averaging $29.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$97
- Organogenesis Inc.$22
Across 14 payments — averaging $208,884 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$2.9M
- Pfizer$44K
What the payments were for
- Food & beverage$2219%
- Education$9781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 3 | $97 |
| Organogenesis Inc. | 1 | $22 |
How this compares
$119 in reported general payments places this provider in the 20th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenotropinSomatropin | 15 | $26,721 |
| HumatropeSomatropin | 12 | $21,783 |
| Testosterone | 56 | $7,542 |
| Levothyroxine Sodium | 35 | $359 |
| Prednisone | 52 | $345 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Boston
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Augusto Caballero-RoblesBoston$150K
- Osama HamdyBoston$117K
- Barbara KahnBoston$105K
- Naomi FisherBoston$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.